1 / 12

Pregabalin Efficacy in Peripheral Neuropathic Pain

Pregabalin Efficacy in Peripheral Neuropathic Pain. Results from the first 15 months of an ongoing open-label study in patients with treatment-refractory pain: Peripheral neuropathic pain analysis. Refractory Pain Study – Peripheral Neuropathic Pain Analysis: Inclusion Criteria.

ronnie
Download Presentation

Pregabalin Efficacy in Peripheral Neuropathic Pain

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Pregabalin Efficacy in Peripheral Neuropathic Pain Results from the first 15 months of an ongoing open-label study in patients with treatment-refractory pain: Peripheral neuropathic pain analysis.

  2. Refractory Pain Study – Peripheral Neuropathic Pain Analysis: Inclusion Criteria • Patients with DPN or PHN who had previously taken part in placebo-controlled, double-blind pregabalin trials • Refractory to: • Gabapentin ≥1800 mg/day AND • Tricyclic antidepressant ≥75 mg/day AND • ≥1 3rd line agent (e.g. AED, narcotic, SSNRI, NSAID) • Refractoriness defined as inadequate pain relief for 2 weeks and/or intolerable side-effects on each of the above • SF-MPQ pain VAS score ≥40 mm • Allowed to continue all pain medications • No inferential testing performed Adapted from D'Urso De Cruz et al. Diabetes 2005; 54 (Suppl. 1): A139 (abstract).

  3. Refractory Pain Study – Peripheral Neuropathic Pain Analysis: Design Overview Relapse Relapse Relapse Relapse “How much has your pain worsened since discontinuing study medication?” Treatment period = 3-month open-label treatment period with pregabalin 150-600 mg/day Drug holiday = pregabalin drug holiday. Only 4 patients did not relapse during drug holidays. Relapse Adapted from D'Urso De Cruz et al. Diabetes 2005; 54 (Suppl. 1): A139 (abstract).

  4. Refractory Pain Study – Pain Reported on Pregabalin Treatment* and During Drug Holidays DH = pregabalin drug holiday. Only 4 patients did not relapse during drug holidays. *15-month open-label pregabalin treatment analysis Adapted from D'Urso De Cruz et al. Diabetes 2005; 54 (Suppl. 1): A139 (abstract).

  5. Refractory Pain Study – Peripheral Neuropathic Pain Analysis: Distribution of Pain Severity at Baseline and 15 Months No/Mild Pain: 0-39; Moderate Pain: 40-69; Severe Pain: ≥70 on SF-MPQ pain VAS 15-month analysis (LOCF). Only 4 patients did NOT relapse during drug holidays. Adapted from D'Urso De Cruz et al. Diabetes 2005; 54 (Suppl. 1): A139 (abstract).

More Related